Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature

Nephrology Dialysis Transplantation

Volumn 28, Issue 9, 2013, Pages 2246-2259

  Manenti, Lucio ^a   Gnappi, Elisa ^a   Vaglio, Augusto ^a   Allegri, Landino ^a   Noris, Marina ^b   Bresin, Elena ^b   Pilato, Francesco Paolo ^a   Valoti, Elisabetta ^b   Pasquali, Sonia ^c   Buzio, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Nephrology and Dialysis Unit   (Italy)

Author keywords

Atypical haemolytic uraemic syndrome; Glomerulonephritis; Nephrotic syndrome; Thrombotic microangiopathy; Vasculitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H AUTOANTIBODY; COMPLEMENT FACTOR I; CYCLOPHOSPHAMIDE; MEMBRANE COFACTOR PROTEIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANAPHYLACTOID PURPURA; C3 GENE; C3 GLOMERULONEPHRITIS; C3 GLOMERULOPATHY; COMPLEMENT FACTOR H GENE; COMPLEMENT FACTOR I GENE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FACTOR H RELATED 1 GENE; FACTOR H RELATED 2 GENE; FACTOR H RELATED 3 GENE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GLOMERULONEPHRITIS; GLOMERULOPATHY; HAPLOTYPE; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEMBRANE COFACTOR PROTEIN GENE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; SMALL VESSEL VASCULITIS; WEGENER GRANULOMATOSIS;

ATYPICAL HAEMOLYTIC URAEMIC SYNDROME; GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; THROMBOTIC MICROANGIOPATHY; VASCULITIS;

ADOLESCENT; ADULT; AGED; COMPLEMENT SYSTEM PROTEINS; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; REVIEW LITERATURE AS TOPIC; YOUNG ADULT;

EID: 84884513282     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft220     Document Type: Review

References (88)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687
2. Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20: 271-277
3. Morita S, Sakai T, Okamoto N et al. Hemolytic uremic syndrome associated with immunoglobulin A nephropathy: a case report and review of cases of hemolytic uremic syndrome with glomerular disease. Intern Med 1999; 38: 495-499
4. Besbas N, Karpman D, Landau D et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431
5. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-846
6. El Karoui K, Hill GS, Karras A et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 137-148
7. De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transpl 2009; 24: 1048-1050
8. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 2010; 49: 7-15
9. Remuzzi G, Galbusera M, Noris M et al. Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and haemolytic uremic syndrome. Blood 2002; 100: 778-785
10. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563
11. Józsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514
12. Skerka C, Józsi M, Zipfel PF et al. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009; 101: 227-232
13. Zhao J, Wu H, Khosravi M et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7: e1002079, 2011
14. Pickering MC, de Jorge EG, Martinez-Barricarte R et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204: 1249-1256
15. Servais A, Noël LH, Roumenina LT et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464
16. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703-712
17. Caprioli J, Castelletti F, Bucchioni S et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385-3395
18. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults. CJASN 2013; 8: 1-9
19. Gnappi E, Allinovi M, Vaglio A et al. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatr Nephrol 2012; 27: 1995-1999
20. Marie J, Lévèque B, Courtecuisse V et al. Hemolytic and uremic syndrome associated with an idiopathic nephrotic syndrome of 4 years' development. Ann Pediatr (Paris) 1969; 16: 7-12
21. Halikowski B, Kucharska K, Sancewicz-Pach K. The hemolyticuremic syndrome in the course of other pathological conditions in children. Pediatr Pol 1971; 46: 591-594
22. Dische FE, Culliford EJ, Parsons V. Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis. Br Med J 1978; 1: 1112-1123
23. Krensky AM, Ingelfinger JR, Grupe WE et al. Hemolytic uremic syndrome and crescentic glomerulonephritis complicating childhood nephrosis. Clin Nephrol 1983; 19: 99-106
24. Siegler RL, Brewer ED, Pysher TJ. Hemolytic uremic syndrome associated with glomerular disease. Am J Kidney Dis 1989; 13: 144-147
25. Friedlander MA, Jacobs GH. Recurrent thrombotic thrombocytopenic purpura associated with membranous glomerulopathy. Am J Kidney 1991; 17: 83-85
26. Bökenkamp A, Hoyer PF, Offner G et al. Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis. Eur J Pediatr 1992; 151: 791-792
27. Liapis H. Thrombotic Microangiopathy involving the kidney: a histopathologic perspective. Hippokratià 2003; 4: 152-158
28. Benz K, Dötsch J, Rascher W et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004; 19: 794-797
29. Koulova L, Alexandrescu D, Dutcher JP et al. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol 2005; 78: 49-54
30. Benz K, Amann K, Dittrich K et al. Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis. Pediatr Nephrol 2007; 22: 2125-2128
31. Suri M, Tran K, Sharma AP et al. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 2008; 40: 807-810
32. Kuppachi S, Chander P, Yoo J. Membranous nephropathy and thrombotic thrombocytopenic purpura treated with rituximab. J Nephrol 2009; 22: 561-564
33. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859
34. Tkaczyk M, Czupryniak A, Owczarek D et al. Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome. Am J Nephrol 2008; 28: 197-202
35. Goldberg RJ, Nakagawa T, Johnson RJ et al. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010; 56: 1168-1174
36. Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-180
37. Katavetin P, Katavetin P. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 359: 205-206
38. Nochy D, Lefaucheur C, Hill G. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 359: 206
39. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007; 2: 529-542
40. Ravani P, Magnasco A, Edefonti A et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1308-1315
41. Cravedi P, Sghirlanzoni MC, Marasà M et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 2011; 33: 461-468
42. George JN. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87: S88-S91
43. Sethi S, Fervenza FC, Zhang Y et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6: 1009-1017
44. Appel GB, Cook HT, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16: 1392-1403
45. Abrera?Abeleda MA, Nishimura C, Smith JL et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589
46. Servais A, Frémeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199
47. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120: 3702-3712
48. Habib R, Courtecuisse V, Leclerc F et al. Etude anatomo-pathologique de 35 observations de syndrome hemolytique et uremique de l'enfant. Arch Fr Pediatr 1969; 26: 391-416
49. Gómez Campderá FJ, Niembro E, López Gómez JM et al. Hemolytic uremic syndrome in a girl, mimicking membranoproliferative glomerulonephritis with a worsening course. Rev Clin Esp 1984; 172: 289-292
50. Pérez AJ, Sobrado J, Courel M et al. Renal thrombotic microangiopathy in a pregnant patient with membranoproliferative glomerulonephritis. Nephron 1988; 49: 86-87
51. Vaziri-Sani F, Holmberg L, Sjöholm AG et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006; 69: 981-988
52. Mak SK, Lo KY, Lo MW et al. Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infection. Hong Kong Med J 2009; 15: 201-208
53. Lorcy N, Rioux-Leclercq N, Lombard ML et al. Three kidneys, two diseases, one antibody? Nephrol Dial Transplant 2001; 26:3811-3813
54. Brackman D, Sartz L, Leh S et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant 2011; 26: 3399-3403
55. Radhakrishnan S, Lunn A, Kirschfink M et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366: 1165-1166
56. Kemper C, Hourcade DE. Properdin: new roles in pattern recognition and target clearance. Mol Immunol 2008; 45: 4048-4056
57. Barber C, Herzenberg A, Aghdassi E et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012; 7: 757-764
58. Hunt BJ, Tueger S, Pattison J et al. Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus 2007; 16: 358-362
59. Benitez L, Mathews M, Mallory GK. Platelet thrombosis with polyarteritis nodosa; report of a case. Arch Pathol 1964; 77: 116-125
60. Stefani FH, Brandt F, Pielsticker K. Periarteritis nodosa and thrombotic thrombocytopenic purpura with serous retinal detachment in siblings. Br J Ophthalmol 1978; 62: 402-407
61. Jordan JM, Manning M, Allen NB. Multiple unusual manifestations of Wegener's granulomatosis: breast mass, microangiopathic hemolytic anemia, consumptive coagulopathy, and low erythrocyte sedimentation rate. Arthritis Rheum 1986; 29: 1527-1531
62. Kuroda Y, Kondo S, Oda K et al. An autopsy case of polyarteritis nodosa associated with multiple cranial neuritis and thrombotic thrombocytopenic purpura. Nihon Naika Gakkai Zasshi 1986; 75: 1291-1296
63. Green J, Brenner B, Gery R et al. Adult hemolytic uremic syndrome associated with nonimmune deposit crescentic glomerulonephritis and alveolar hemorrhage. Am J Med Sci 1988; 296: 121-125
64. Heptinstall R. Hemolytic Uremic Syndrome. In Heptinstall R. (ed). Boston, MA, USA: Pathology of the Kidney. 1992, pp. 1163-1234
65. Hirsch DJ, Jindal KK, Trillo AA. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis and thrombotic microangiopathy. Am J Kidney Dis 1995; 26: 385-386
66. Filler G, von Bredow MA, Gröne HJ et al. A child with haemolytic uraemic syndrome: do we have to care about aetiological heterogeneity? Nephrol Dial Transplant 1997; 12:1064-1066
67. Stefanidis I, Helmchen U, Schmitt H et al. Coincidence of haemolytic uraemic syndrome and c-ANCA-associated rapidly progressive glomerulonephritis. Nephrol Dial Transplant 1998; 13: 1818-1821
68. Hollenbeck M, Kutkuhn B, Aul C et al. Haemolytic-uraemic syndrome and thrombotic-thrombocytopenic purpura in adults: clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 1998; 13: 76-81
69. Lim HE, Jo SK, Kim SW et al. A case of Wegener's granulomatosis complicated by diffuse pulmonary hemorrhage and thrombotic thrombocytopenic purpura. Korean J Intern Med 1998; 13: 68-71
70. Rizvi MA, Vesely SK, George JN et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40: 896-901
71. Yamasaki S, Tominaga M, Kawakami A et al. Polyarteritis nodosa complicated by thrombotic thrombocytopenic purpura. Ann Rheum Dis 2001; 60: 541-542
72. Sato T, Hanaoka R, Ohshima M. Thrombotic thrombocytopenic purpura in connective tissue disease. Rheumatology 2002; 28: 348-356
73. Suzuki M, Ohkawara M, Kojima T et al. A case of microscopic polyangiitis complicated later with thrombotic thrombocytopenic purpura. Lung Perspect 2004; 12: 134-140
74. Al-Toma AA, Brink MA, Hagen EC. Henoch-Schönlein purpura presenting as terminal ileitis and complicated by thrombotic microangiopathy. Eur J Intern Med 2005; 16: 510-512
75. Fujimura Y, Murakami S, Kuroda T et al. A case of ANCA associated vasculitis complicated with thrombotic thrombocytopenic purpura. J Chubu Rheum Assoc 2006; 37: 106-107
76. Yamazaki M, Takei T, Otsubo S. Wegener's granulomatosis complicated by intestinal ulcer due to cytomegalovirus infection and by thrombotic thrombocytopenic purpura. Intern Med 2007; 46: 1435-1440
77. Yoshioka K, Hattori T, Isaka Y et al. Thrombotic microangiopathy due to malignant hypertension following corticosteroid therapy for microscopic polyangiitis. Intern Med 2007; 46: 785-788
78. Nagai K, Kotani T, Takeuchi T et al. Successful treatment of thrombotic thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangiitis. Mod Rheumatol 2008; 18: 643-646
79. Zhang W, Shi H, Ren H. Clinicopathological characteristics and outcome of Chinese patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a 9-year retrospective study. Nephron Clin Pract 2009; 112: 177-183
80. Kobayashi S, Inokuma S. Intrapulmonary hemorrhage in collagen-vascular diseases includes a spectrum of underlying conditions. Inter Med 2009; 48: 891-897
81. Watanabe H, Kitagawa W, Suzuki K. Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies. Clin Exp Nephrol 2010; 14: 598-601
82. Asamiya Y, Moriyama T, Takano M et al. Successful treatment with rituximab in a patient with TTP secondary to severe ANCAassociated vasculitis. Intern Med 2010; 49: 1587-1591
83. Yamauchi Y, Nagatoya K, Okuno A et al. Successful treatment for thrombotic thrombocytopenic purpura complicated with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis. NDT plus 2010; 3: 279-281
84. Mandai S, Nagahama K, Tsuura Y et al. Recovery of renal function in a dialysis-dependent patient with microscopic polyangiitis and both myeloperoxidase anti-neutrophil cytoplasmic antibodies and anti-glomerular basement membrane antibodies. Intern Med 2011; 50: 1599-1603
85. Manenti L, Vaglio A, Buzio C. New aspects of membranoproliferative glomerulonephritis. N Engl J Med 2012; 367: 86
86. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
87. Köse O, Zimmerhackl LB, Jungraithmayr T et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36: 669-672
88. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756